Do you want to read an article? Please log in or register.
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
Breast Cancer
Related content
SPECIAL REPORT
Breast Cancer
Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study
CHICAGO 2025
Breast Cancer
LBA109: ASCENT-04/KEYNOTE-D19: Sacituzumab govitecan plus pembrolizumab improves PFS in first-line PD-L1–positive metastatic TNBC
Genitourinary Cancer
Updated Findings Support Enfortumab Vedotin plus Pembrolizumab as Standard of Care in Advanced Urothelial Cancer
ESMO 2025
Breast Cancer
ASCENT-04/KEYNOTE-D19: Sacituzumab govitecan plus pembrolizumab maintains QoL and delays functional decline in patients with PD-L1-positive metastatic TNBC
SPECIAL REPORT
Gynecologic Cancer
Establishing Pembrolizumab Plus Chemotherapy as a New Standard for dMMR Endometrial Cancer
Breast Cancer
Tibremciclib or Placebo Plus Fulvestrant in Hormone Receptor-Positive and ERBB2-Negative Advanced Breast Cancer After Endocrine Therapy: A Randomized Clinical Trial
JAMA Oncol
Tao Z, Zhang J, Zheng Q, Wang Y, Cai L, Xu H, Xu X, Kong X, Ding S, Hao C, Wang H, Zong H, Jin X, Wang X, Li Y, Yang X, Li W, Du X, Chen H, Wu P, Li P, Mao L, Ding L, Hu X, Wang S
doi: 10.1001/jamaoncol.2025.2092
RECOMMENDED
Breast Cancer
Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial
★ 3
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
J Clin Oncol
Chen X, Huang J, Shi H, Zhu J, Wu W, Ye G, He Q, Shi Y, Zhang A, Xie X, Wang X, Chen X, Wu W, Wu J, Li Z, Li Z, Dai Y, Ren W, Shao Q, Chen Y, Zeng Y, Zhang F, Dong S, Pegram MD, Shen K
doi: 10.1200/JCO-25-02412
CHICAGO 2025
Breast Cancer
LBA4: SERENA-6: Switching to camizestrant plus CDK4/6 inhibitor significantly delays progression in HR-positive, HER2-negative advanced breast cancer with an emergent ESR1 mutation in first line
SABCS 2025
Breast Cancer